Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

Journal of Pharmaceutical Sciences

Volumn 90, Issue 11, 2001, Pages 1829-1837

  Perloff, Michael D ^a   Von Moltke, Lisa L ^a   Marchand, James E ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Highly active antiretroviral therapy (HAART); HIV protease inhibitors; Induction; Multidrug resistance associated protein (MRP1); P glycoprotein (P gp); Ritonavir

Indexed keywords

CARBOXYFLUORESCEIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; RITONAVIR; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; INTESTINE CARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0035149585     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.1133     Document Type: Article

References (47)

1. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
4. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
5. Oral absorption of the HIV protease inhibitors: A current update
6. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
7. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
8. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication
9. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins
10. Evidence for different ABC-transporters in caco-2 cells modulating drug uptake
11. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells
12. Mrpl multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells
13. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in caco-2 cell monolayers
14. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (caco-2)
15. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
16. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
17. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
18. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus
19. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
20. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents
21. Role of Pgp and MRP in cellular influx/efflux of protease inhibitors in vitro
22. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy
23. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
24. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
25. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
26. Modulation of P-glycoprotein function in human lymphocytes and caco-2 cell monolayers by HIV-1 protease inhibitors
27. Alprazolam-ritonavir interaction: Implications for product labeling
28. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
29. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
30. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
31. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
32. Human colonic adenocarcinoma cells. I. Establishment and description of a new line
33. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists
34. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level
35. Interaction of drugs with P-glycoprotein in brain capillaries
36. Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms
37. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
38. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: Testing drug affinities to the secretory intestinal multidrug transporter
39. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
40. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids
41. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion
42. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein
43. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
44. Resistance, fitness, adherence, and potency: Mapping the paths to virologic failure
45. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
46. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
47. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors